Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 12 04:00PM ET
Dollar change
Percentage change
Index- P/E11.68 EPS (ttm)0.45 Insider Own28.05% Shs Outstand47.65M Perf Week-6.89%
Market Cap254.07M Forward P/E31.00 EPS next Y0.17 Insider Trans-0.82% Shs Float34.68M Perf Month-1.13%
Income21.59M PEG- EPS next Q-0.22 Inst Own55.26% Short Float9.50% Perf Quarter15.57%
Sales235.64M P/S1.08 EPS this Y-42.22% Inst Trans-2.11% Short Ratio5.31 Perf Half Y110.80%
Book/sh1.12 P/B4.70 EPS next Y-34.62% ROA9.54% Short Interest3.29M Perf Year81.10%
Cash/sh1.99 P/C2.65 EPS next 5Y- ROE57.54% 52W Range2.13 - 7.73 Perf YTD21.71%
Dividend Est.- P/FCF9.46 EPS past 5Y- ROI17.12% 52W High-31.82% Beta1.30
Dividend TTM- Quick Ratio1.50 Sales past 5Y-0.59% Gross Margin73.40% 52W Low147.42% ATR (14)0.39
Dividend Ex-Date- Current Ratio1.57 EPS Y/Y TTM15796.55% Oper. Margin14.12% RSI (14)46.10 Volatility6.02% 7.47%
Employees185 Debt/Eq2.09 Sales Y/Y TTM3.34% Profit Margin9.16% Recom3.00 Target Price4.33
Option/ShortYes / Yes LT Debt/Eq1.36 EPS Q/Q308.66% Payout0.00% Rel Volume0.36 Prev Close5.49
Sales Surprise-1.84% EPS Surprise-13.33% Sales Q/Q9.90% EarningsFeb 29 AMC Avg Volume619.70K Price5.27
SMA20-0.73% SMA50-6.37% SMA20029.31% Trades Volume221,459 Change-4.01%
Date Action Analyst Rating Change Price Target Change
Sep-28-21Upgrade Citigroup Neutral → Buy $11
Jun-25-20Resumed BofA/Merrill Underperform $9
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Apr-11-24 06:00PM
Apr-03-24 05:30PM
Mar-22-24 09:25AM
Mar-20-24 08:30AM
Mar-02-24 08:29AM
09:55AM Loading…
Mar-01-24 09:55AM
Feb-29-24 04:41PM
Feb-27-24 06:30PM
Feb-22-24 04:10PM
Feb-15-24 04:10PM
08:30AM Loading…
Feb-13-24 08:30AM
Jan-31-24 12:58PM
Jan-11-24 04:07PM
Jan-06-24 11:02AM
Dec-11-23 08:30AM
Nov-20-23 11:47AM
Nov-06-23 05:15PM
Nov-03-23 12:16PM
Nov-02-23 07:42PM
Oct-19-23 04:14PM
Oct-14-23 12:30PM
05:30PM Loading…
Oct-04-23 05:30PM
Sep-22-23 07:57AM
Sep-21-23 04:10PM
Aug-31-23 04:07PM
Aug-08-23 08:30AM
Aug-04-23 12:36PM
Aug-03-23 05:17PM
Jul-20-23 04:15PM
Jun-13-23 09:30AM
Jun-06-23 05:03PM
Jun-04-23 09:00AM
May-28-23 10:06AM
May-22-23 11:07AM
May-05-23 05:15PM
May-04-23 05:32PM
Apr-20-23 04:15PM
Apr-17-23 06:49AM
Apr-11-23 05:15PM
Mar-14-23 08:30AM
Mar-06-23 09:48AM
Mar-03-23 05:15PM
Mar-02-23 04:05PM
Feb-28-23 04:15PM
Feb-19-23 02:05PM
Feb-16-23 04:31PM
Feb-07-23 05:30PM
Feb-01-23 08:30AM
Jan-25-23 06:19AM
Jan-12-23 04:15PM
Jan-11-23 05:30PM
Jan-09-23 08:55AM
Dec-20-22 08:31AM
Dec-15-22 03:39PM
Dec-07-22 06:03PM
Dec-05-22 05:30PM
Dec-01-22 08:36AM
Nov-28-22 09:55AM
Nov-22-22 09:15AM
Nov-21-22 05:25PM
Nov-17-22 09:40AM
Nov-14-22 10:10AM
Nov-11-22 10:20AM
Nov-09-22 10:43AM
Nov-07-22 01:02PM
Nov-04-22 12:29PM
Nov-03-22 06:45PM
Nov-02-22 05:30PM
Oct-27-22 04:05AM
Oct-20-22 04:15PM
Oct-12-22 09:31AM
Oct-04-22 05:30PM
Sep-21-22 11:35AM
Sep-20-22 04:05PM
Sep-11-22 05:15AM
Sep-06-22 04:15PM
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AUERBACH ALAN HPresident and CEOJan 03 '24Sale4.4941,396185,6986,936,947Jan 05 06:56 PM
NOUGUES MAXIMO FChief Financial OfficerJan 03 '24Sale4.4915,68270,348128,666Jan 05 06:49 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJan 03 '24Sale4.4912,95658,11999,970Jan 05 07:00 PM
HUNT DOUGLAS MSee RemarksJan 03 '24Sale4.498,35837,493103,319Jan 05 06:42 PM
Wong Alvin FChief Scientific OfficerJan 03 '24Sale4.497,73334,68998,214Jan 05 07:03 PM
Wong Alvin FChief Scientific OfficerDec 04 '23Sale3.762801,05397,934Jan 10 04:41 PM
MILLER MICHAEL PATRICKDirectorNov 07 '23Sale2.8325,00070,80243,358Nov 09 04:19 PM
AUERBACH ALAN HPresident and CEOJul 03 '23Sale3.3160,698200,9836,978,343Jul 06 07:03 PM
NOUGUES MAXIMO FChief Financial OfficerJul 03 '23Sale3.3114,68048,608144,348Jul 06 07:12 PM
Ludwig Jeffrey JeromeChief Commercial OfficerJul 03 '23Sale3.3112,10340,075112,926Jul 06 07:08 PM
HUNT DOUGLAS MSee RemarksJul 03 '23Sale3.317,80925,857111,677Jul 06 07:06 PM
Wong Alvin FChief Scientific OfficerJul 03 '23Sale3.316,93822,973105,947Jul 06 07:16 PM
Senderowicz AdrianDirectorJun 13 '23Sale3.4527,00093,2800Jun 15 09:03 PM
WILSON TROY EDWARDDirectorJun 13 '23Sale3.4527,00093,269350Jun 15 09:14 PM
MOYES JAY MDirectorJun 13 '23Sale3.4522,00075,97016,322Jun 15 09:10 PM
MILLER MICHAEL PATRICKDirectorJun 13 '23Sale3.4513,50046,63041,358Jun 15 08:28 PM
Dorval AllisonDirectorJun 13 '23Sale3.4510,00034,50017,000Jun 15 09:01 PM
Stuglik Brian MDirectorJun 13 '23Sale3.469,90034,25231,958Jun 15 09:06 PM
Wong Alvin FChief Scientific OfficerJun 02 '23Sale3.45269928112,885Jun 06 04:36 PM